Stock Events

Stock Events

GridAI Technologies 

$2.51
80
+$0.03+1.41% Tuesday 19:48

Statistics

Day High
2.54
Day Low
2.37
52W High
5.84
52W Low
0.97
Volume
52,010
Avg. Volume
-
Mkt Cap
8.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25MayExpected
Q1 2025
Q3 2025
Q4 2025
Next
-1.23
-0.9
-0.56
-0.23
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-36.6MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GRDX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other diseases, competing in the biopharmaceutical space with a focus on serious conditions, similar to FWBI's focus on gastrointestinal diseases.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences operates in the biopharmaceutical sector, focusing on antiviral drugs for HIV, hepatitis B, hepatitis C, and influenza, presenting competition in the broad biopharma market.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie competes in the development of biopharmaceuticals, including treatments for conditions like Crohn's disease and ulcerative colitis, directly competing with FWBI's gastrointestinal focus.
AMGEN
AMGN
Mkt Cap178B
Amgen focuses on human therapeutics, including treatments for inflammatory diseases, which could overlap with FWBI's development of treatments for gastrointestinal disorders.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals is known for its innovative biopharmaceuticals, competing in areas that could intersect with FWBI's work on gastrointestinal and inflammatory diseases.
Biogen
BIIB
Mkt Cap27.62B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, competing in the broader biopharmaceutical space and targeting chronic conditions, similar to FWBI.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca operates globally in the biopharmaceutical sector, with a wide range of treatments that could compete with FWBI's gastrointestinal disease focus.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is a global biopharmaceutical company with a broad portfolio, including treatments for inflammatory diseases, potentially competing with FWBI's product pipeline.
Merck
MRK
Mkt Cap277.02B
Merck & Co. focuses on pharmaceuticals across various areas, including immunology, which could place it in competition with FWBI's focus on gastrointestinal diseases.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb operates in the biopharmaceutical field, with a focus on serious diseases, including a portfolio that could compete with FWBI's gastrointestinal treatments.

About

GridAI Technologies Corp. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its pipeline includes Latiglutenase, Capeserod, Adrulipase, and Niclosamide. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Show more...
CEO
Mr. Jason David Sawyer
Employees
2
Country
United States
ISIN
US33749P5070

Listings

XNAS
US
GRDX
BOATS
BOATS
GRDX.BOATS

0 Comments

Share your thoughts

FAQ

What is GridAI Technologies stock price today?▼
The current price of GRDX is $2.51 USD — it has increased by +1.41% in the past 24 hours. Watch GridAI Technologies stock price performance more closely on the chart.
What is GridAI Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange GridAI Technologies stocks are traded under the ticker GRDX.
What is GridAI Technologies market cap?▼
Today GridAI Technologies has the market capitalization of 8.44M
When is the next GridAI Technologies earnings date?▼
GridAI Technologies is going to release the next earnings report on May 25, 2026.
What is GridAI Technologies revenue for the last year?▼
GridAI Technologies revenue for the last year amounts to 0 USD.
What is GridAI Technologies net income for the last year?▼
GRDX net income for the last year is -36.6M USD.
How many employees does GridAI Technologies have?▼
As of May 06, 2026, the company has 2 employees.
In which sector is GridAI Technologies located?▼
GridAI Technologies operates in the Energy sector.
When did GridAI Technologies complete a stock split?▼
The last stock split for GridAI Technologies was on August 18, 2025 with a ratio of 1:3.
Where is GridAI Technologies headquartered?▼
GridAI Technologies is headquartered in Edinburgh, United States.